PHILADELPHIA — (Sept. 21, 2021) — Mutations in the ARID1A gene are present in more than 50% of ovarian clear cell carcinomas (OCCC), for which effective treatments are lacking. Scientists at The Wi…
PHILADELPHIA — (Sept. 1, 2021) — The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious diseases, welcomes Amelia Escolano, Ph.D., and Nan Zhang, Ph….
PHILADELPHIA — (Aug. 31, 2021) — The Wistar Institute announces the appointment of Italo Tempera, Ph.D., as Associate Director for Cancer Research Career Enhancement at the Institute’s Cancer Cente…
PHILADELPHIA — (Aug. 25, 2021) — According to a study by The Wistar Institute, the tumor suppressor Parkin, whose levels are reduced in different cancer types, causes acute metabolic and oxidative …
PHILADELPHIA — (Aug. 17, 2021) — The Wistar Institute announces that the National Institutes of Health (NIH) granted a five-year, $29.15 million Martin Delaney Collaboratories for HIV Cure Research…
PHILADELPHIA — (July 30, 2021) — The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious diseases, announces the appointment of Daniel Claiborne, Ph.D…
PHILADELPHIA — (July 20, 2021) — Alternative polyadenylation (APA) is an RNA processing mechanism that regulates gene expression by generating different ends on RNA transcripts of the same gene. Th…
PHILADELPHIA — (June 29, 2021) — New biomarkers that predict HIV remission after antiretroviral therapy (ART) interruption are critical for the development of new therapeutic strategies that can ac…
PHILADELPHIA — (June 2, 2021) — The Wistar Institute, an international biomedical research leader with special expertise in cancer, immunology and infectious disease research and vaccine developmen…
PHILADELPHIA — (June 1, 2021) — The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious diseases, announces the appointment of Noam Auslander, Ph.D., …
